Business
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
CAMBRIDGE, Mass., May 15, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal.
About this update from Amylyx Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2517,"height":588,"url":"https://media.zenfs.com/en/business-wire.com/2103a72a75c132ee60ffcdd5db2a7846"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TCiNAQlmzz4ePqInrJomwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNA--/https://media.zenfs.com/en/business-wire.com/2103a72a75c132ee60ffcdd5db2a7846","width":960,"height":224},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_Xpdj7t.II1REnINktUgwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE1MA--/https://media.zenfs.com/en/business-wire.com/2103a72a75c132ee60ffcdd5db2a7846","width":640,"height":150},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VAa8xNE6xk9XHY9WhARKCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjA-/https://media.zenfs.com/en/business-wire.com/2103a72a75c132ee60ffcdd5db2a7846","width":1200,"height":280}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic control, vision, and overall symptom burden","length":335,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AMX0035 was generally well-tolerated, consistent with previously presented safety data","length":86,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Company continues to work with the FDA on a Phase 3 trial in Wolfram syndrome","length":81,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":502,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 15, 2026--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal.","length":460,"tagName":"p"},{"type":"text","content":"The publication reports Week 24 and Week 48 results from the Phase 2 open‑label...